Synergy Pharmaceuticals Inc (NASDAQ:SGYP)‘s stock had its “buy” rating reaffirmed by Zacks Investment Research in a note issued to investors on Monday, Market Beat.com reports. They currently have a $4.25 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 18.72% from the company’s previous close. According to […]
